Vitis labruscana Bailey leaf extract improves vascular function markers including platelet aggregation: A randomized,...

Area of Science:

• Cardiovascular research
• Nutritional science
• Pharmacology

Background:

• Cardiovascular diseases (CVDs) are a leading global cause of mortality.
• Platelet aggregation is a critical factor in thrombosis and CVD development.
• Preliminary studies indicate Vitis labruscana Bailey leaf extract (HP-01) may offer cardioprotective and antithrombotic benefits.

Purpose of the Study:

• To investigate the impact of HP-01 supplementation on blood flow parameters in individuals at risk for CVD.
• Key parameters assessed include platelet aggregation (closure time), activated partial thromboplastin time (aPTT), and systolic blood pressure (SBP).

Main Methods:

• A 12-week, randomized, double-blind, placebo-controlled trial was conducted with 80 participants exhibiting CVD risk factors.
• Participants received either HP-01 (1800 mg/day) or a placebo, administered thrice daily.
• Evaluated endpoints included changes in platelet aggregation, peripheral arterial tonometry index, blood pressure, prothrombin time, aPTT, and lipid profiles.

Main Results:

• HP-01 supplementation led to a significant reduction in platelet aggregation (closure time) compared to the placebo group (p=0.0252).
• A significant increase in aPTT (p=0.0402) and a significant decrease in systolic blood pressure (SBP) (p=0.0398) were observed in the HP-01 group.
• No serious adverse reactions were reported in either the HP-01 or placebo groups.

Conclusions:

• HP-01 supplementation demonstrates potential benefits for cardiovascular health.
• The extract appears to improve hemostatic function and reduce blood pressure in individuals with CVD risk factors.
• Further research into HP-01 as a supportive measure for cardiovascular health is warranted.